Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial
Resource Type
Article
Authors
Popat, Uday R ; Mehta, Rohtesh S ; Bassett, Roland ; Chen, Julianne ; Valdez, Benigno C ; Kawedia, Jitesh ; Ahmed, Sairah ; Alousi, Amin M ; Anderlini, Paolo ; Al-Atrash, Geath ; Bashir, Qaiser ; Ciurea, Stefan O ; Hosing, Chitra M ; Im, Jin S ; Jones, Roy ; Kebriaei, Partow ; Khouri, Issa ; Marin, David ; Nieto, Yago ; Olson, Amanda ; Oran, Betul ; Parmar, Simrit ; Rezvani, Katayoun ; Qazilbash, Muzaffar H ; Shah, Nina ; Srour, Samer A ; Shpall, Elizabeth J ; Champlin, Richard E ; Andersson, Borje S
Source
In The Lancet Haematology November 2018 5(11):e532-e542
Subject
Primary Research Articles
Language
ISSN
2352-3026